Provectus Pharmaceuticals (PVCT) PV-10′s Unique Bystander Effect
Provectus Pharmaceuticals, Inc. (PVCT), which is developing cancer therapies similar to companies like Dendreon Corporation (DNDN) and Genta Inc. (GETA), has found that its PV-10 Phase II candidate demonstrates a unique “bystander effect” when treating nearby legions.
Provectus Pharmaceuticals, Inc. (PVCT), a biotechnology company focused on developing cancer and psoriasis treatments using the Rose Bengal compound, found in recent Phase I and II studies that its lead PV-10 compound demonstrates a unique “bystander effect” that results in improvements in other melanoma tumors that were not directly treated.
The occurrence suggests that PV-10 is able to not only safely and effectively treat cancerous tumors, but also jumpstart the body’s own immune system to combat cancer in adjacent regions that were not directly treated. As a result, PV-10 could be even more effective than first envisioned when it comes to completely eradicating cancer from a patient.
PV-10 studies have shown that thick, oily red dye exhibits preferential uptake into lysosomes of cancer cells but it is excluded from normal cells, resulting in selective necrosis in multiple melanoma lines. Essentially, this means that the Rose Bengal compound is able to selectively kill cancer cells without damaging the surrounding cells.
Meanwhile, scientists also noticed that bystander lesions that were not directly treated also improved, in about 50% of cases, within the study follow-up. The company believes that the exposure of tumor antigens in context from the cells that are destroyed is what promotes the activity, but further study is necessary to show more completely how it works.
Over the past 50+ years, scientists have also clearly demonstrated that the compound is not metabolized in the body. Rather, it is excreted rapidly and has minimal toxicity in healthy tissues. These attributes have helped PV-10 conduct current compassionate use studies under the auspices of the FDA and could help fast-track PV-10 further through any remaining clinical trial.
In the end, Provectus’ PV-10 candidate is showing great promise in not only treating tumors, but also jumpstarting the body’s own immune system to fight surrounding cancer cells. As a result, scientists are increasingly confident in the drug’s ability to one-day make a lasting impact in the world’s fight against cancer.
Click Here to Learn More about Provectus Pharmaceuticals (PVCT)
CONTACT: 888-288-5215 · Please read our Full Disclaimer pertaining to this article.
Request a Detailed Report on Provectus Pharmaceuticals Inc. (PVCT)